Latest Insider Transactions at Marinus Pharmaceuticals, Inc. (MRNS)
This section provides a real-time view of insider transactions for Marinus Pharmaceuticals, Inc. (MRNS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MARINUS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MARINUS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 11
2025
|
Elan Ezickson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,300
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 11
2025
|
Timothy M Mayleben Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,300
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 11
2025
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
48,077
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 11
2025
|
Marvin Johnson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,101
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 11
2025
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
55,570
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 11
2025
|
Seth H. Z. Fischer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,300
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 11
2025
|
Christine Berni Silverstein Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,702
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 11
2025
|
Scott Braunstein CHAIRMAN AND CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
179,536
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 11
2025
|
Christina Shafer CHIEF COMMERCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
48,628
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 11
2025
|
Steven Pfanstiel CFO AND COO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,470
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Elan Ezickson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,600
-78.9%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Timothy M Mayleben Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
13,957
-100.0%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Timothy M Mayleben Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,600
-66.67%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,186
-20.22%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Marvin Johnson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,389
-43.15%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,155
-23.59%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Seth H. Z. Fischer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,707
-84.67%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Christine Berni Silverstein Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,398
-66.65%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Scott Braunstein CHAIRMAN AND CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
125,064
-41.06%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Christina Shafer CHIEF COMMERCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,778
-27.86%
|
$0
$0.55 P/Share
|
|
Feb 07
2025
|
Steven Pfanstiel CFO AND COO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,303
-21.69%
|
$0
$0.55 P/Share
|
|
Jan 21
2025
|
Marvin Johnson Director |
SELL
Open market or private sale
|
Direct |
1,610
-11.42%
|
$0
$0.54 P/Share
|
|
Jan 21
2025
|
Elan Ezickson Director |
SELL
Open market or private sale
|
Direct |
1,600
-12.8%
|
$0
$0.54 P/Share
|
|
Oct 10
2024
|
Timothy M Mayleben Director |
SELL
Bona fide gift
|
Indirect |
8,300
-17.23%
|
-
|
|
Aug 14
2024
|
Scott Braunstein CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
5,933
+1.91%
|
$5,933
$1.1 P/Share
|
|
Aug 05
2024
|
Scott Braunstein CHAIRMAN AND CEO |
SELL
Open market or private sale
|
Direct |
12,145
-3.91%
|
$12,145
$1.13 P/Share
|
|
Aug 05
2024
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,828
-6.23%
|
$4,828
$1.13 P/Share
|
|
Aug 05
2024
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
SELL
Open market or private sale
|
Direct |
3,621
-5.67%
|
$3,621
$1.13 P/Share
|
|
Aug 05
2024
|
Christina Shafer CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,820
-5.36%
|
$3,820
$1.14 P/Share
|
|
Aug 05
2024
|
Steven Pfanstiel CFO AND COO |
SELL
Open market or private sale
|
Direct |
4,657
-5.52%
|
$4,657
$1.13 P/Share
|
|
Jun 18
2024
|
Marvin Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+14.02%
|
-
|
|
Jun 18
2024
|
Sara Nochur |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+14.79%
|
-
|
|
Jun 18
2024
|
Timothy M Mayleben Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+8.62%
|
-
|
|
Jun 18
2024
|
Sarah B. Noonberg |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+14.02%
|
-
|
|
Jun 18
2024
|
Christine Berni Silverstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+14.02%
|
-
|
|
Jun 18
2024
|
Scott Braunstein CHAIRMAN AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
37,300
+10.71%
|
-
|
|
Jun 18
2024
|
Steven Pfanstiel CFO AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
12,733
+13.1%
|
-
|
|
Jun 18
2024
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,918
+12.34%
|
-
|
|
Jun 18
2024
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
10,918
+14.6%
|
-
|
|
Jun 18
2024
|
Christina Shafer CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,918
+13.29%
|
-
|
|
Jun 18
2024
|
Charles Austin |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+15.89%
|
-
|
|
Jun 18
2024
|
Elan Ezickson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+15.54%
|
-
|
|
Jun 18
2024
|
Seth H. Z. Fischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+15.11%
|
-
|
|
Mar 27
2024
|
Scott Braunstein CHAIRMAN AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+15.46%
|
$200,000
$4.28 P/Share
|
|
Feb 20
2024
|
Martha E Manning SVP, GEN. COUNSEL & CORP. SEC. |
SELL
Open market or private sale
|
Direct |
1,894
-3.45%
|
$17,046
$9.57 P/Share
|
|
Feb 20
2024
|
Christina Shafer CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,153
-3.45%
|
$19,377
$9.56 P/Share
|
|
Feb 16
2024
|
Scott Braunstein CHAIRMAN AND CEO |
SELL
Open market or private sale
|
Direct |
11,850
-5.03%
|
$106,650
$9.94 P/Share
|
|
Feb 16
2024
|
Steven Pfanstiel CFO AND COO |
SELL
Open market or private sale
|
Direct |
3,092
-4.13%
|
$27,828
$9.97 P/Share
|
|
Feb 16
2024
|
Joseph Hulihan CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,814
-4.05%
|
$25,326
$9.98 P/Share
|
|
Jan 18
2024
|
Seth H. Z. Fischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,600
+30.21%
|
-
|